AVTX Director Kevin Lind Files Initial Form 3 Showing Zero Holdings
Rhea-AI Filing Summary
Avalo Therapeutics, Inc. (AVTX) director Kevin Robert Lind filed an initial Form 3 reporting that he does not beneficially own any securities of the issuer. The Form 3 lists the qualifying event date as 10/01/2025 and is signed by Donald R. Reynolds by power of attorney on 10/02/2025. The filing gives the reporter's address as 1500 Liberty Ridge Drive, Suite 321, Wayne, PA 19087.
Positive
- None.
Negative
- None.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What did Kevin Robert Lind report on the Form 3 for AVTX?
The Form 3 states that Kevin Robert Lind does not beneficially own any securities of Avalo Therapeutics as of the event date 10/01/2025.
When was the Form 3 event date and who signed the filing?
The event date is 10/01/2025 and the Form 3 was signed by Donald R. Reynolds by power of attorney on 10/02/2025.
What is the reporting person's relationship to Avalo Therapeutics (AVTX)?
The filing indicates the reporting person is a Director of Avalo Therapeutics.
Does the Form 3 disclose any derivative or non-derivative holdings?
No. The Form 3 explicitly states: "No securities are beneficially owned."
What address is listed for the reporting person on the Form 3?
The address listed is 1500 Liberty Ridge Drive, Suite 321, Wayne, PA 19087.